NONOF News and Press, Novo-Nordisk A/S

2024-06-25 17:50:06 ET Summary Roche Holding AG stock has seen a 13% price rise in the past month following positive trial results for its obesity treatment. Weight management and associated diseases like diabetes have huge potential, as seen from the examples of Novo Nordisk and ...

2024-06-24 13:05:06 ET Summary Zealand Pharma A/S petrelintide showed promising results in a phase 1b study, with patients achieving up to 8.6% weight loss over 16 weeks at the highest dose. The global obesity market could reach $77 billion in 2030. Survodutide, dapiglutide, a...

2024-06-21 09:44:16 ET More on Hims & Hers Health Hims & Hers: The Undervalued Gem Poised For Growth Hims & Hers: Compounded Semaglutide Boost Unlikely To Last - Moderate Risks Ahead Hims & Hers: Ready For Takeoff Hims & Hers cut to Neutra...

2024-06-20 09:02:55 ET More on Eli Lilly Eli Lilly: The Party Is Probably Nearing The End Eli Lilly And Alzheimer's Disease: The Paucity Of Progress Eli Lilly: The Road To Approval Of Donanemab Is Open Eli Lilly oral weight-loss candidate orforglipron is pote...

2024-06-18 11:26:22 ET Summary Novo Nordisk is a growth stock that continues to pleasantly surprise me and investors with the pace of its development of product candidates for the treatment of endocrine diseases. The company's share price reflects optimism about its diabetes franc...

2024-06-18 11:16:16 ET More on Novo Nordisk Novo Nordisk: The Market Is Right, Don't Fight Against It Novo Nordisk: Not The Best Investment Right Now, But A Great Case Study Novo Nordisk: Considerable Growth Beyond Ozempic Ozempic drives more demand for small...

2024-06-17 11:30:03 ET Summary Amgen continues to delight investors with the growth in sales of its key blockbusters and the expansion of its portfolio of medications. In mid-June, Amgen pleased investors by announcing that the FDA had approved Blincyto to treat certain patients w...

2024-06-15 07:28:25 ET More on Novo Nordisk Novo Nordisk: The Market Is Right, Don't Fight Against It Novo Nordisk: Not The Best Investment Right Now, But A Great Case Study Novo Nordisk: Considerable Growth Beyond Ozempic Employee benefits survey finds marke...

2024-06-14 10:24:55 ET Summary Structure Therapeutics Inc. shares surged over 50% on positive GSBR-1290 data, competing with other oral GLP-1R clinical rivals. However, GSBR-1290's efficacy at week 12 fell below Novo Nordisk's amycretin, but still competitive in the obesity treatm...

2024-06-14 08:01:46 ET More on Eli Lilly, Novo Nordisk, etc. Eli Lilly: The Road To Approval Of Donanemab Is Open Eli Lilly and Company (LLY) Goldman Sachs 45th Annual Global Healthcare Conference Is It Possible Eli Lilly Is Breaking Out To New All-Time Highs? ...